Healthcare Industry News: ORGANOGENESIS
News Release - January 6, 2006
NitroMed Promotes Michael Sabolinski, M.D. to the Position of Chief Medical Officer
LEXINGTON, Mass.--(HSMN NewsFeed)--Jan. 6, 2006--NitroMed, Inc. (NASDAQ:NTMD ) announced that Michael L. Sabolinski, M.D. has been named Chief Medical Officer for the Company effective today. Dr. Sabolinski succeeds company co-founder Manuel Worcel, M.D. in this position. As Chief Medical Officer, Dr. Sabolinski will oversee Clinical Research, Regulatory Affairs, Medical Affairs and Quality Assurance, serve on the Executive Committee and report to Michael D. Loberg, Ph.D., President and Chief Executive Officer.Dr. Sabolinski joined NitroMed in 2002 as Senior Vice President for Clinical Development and Regulatory Affairs, with over twenty years of experience in the pharmaceutical industry. In his former role, Dr. Sabolinski directed the successful African American Heart Failure (A-HeFT) clinical trial, which led to the FDA approval of BiDil® in June 2005. Dr. Sabolinski joined NitroMed from ORGANOGENESIS, Inc. where he held several positions including President and Chief Executive Officer, Head of Clinical Research and Regulatory Affairs, and Head of Corporate Development. At ORGANOGENESIS, Dr. Sabolinski successfully managed the team that secured two FDA approvals of a living skin substitute. In addition, he was instrumental in developing a partnership with Novartis Pharmaceuticals to globally market ORGANOGENESIS' leading skin product. Prior to ORGANOGENESIS, Dr. Sabolinski was Therapeutic Area Head of Cardiovascular and Consumer/OTC products at Sandoz Pharmaceuticals Corporation. He earned his M.D. from the State University of New York at Buffalo and an M.S. in Biochemistry from New York University Graduate School of Arts and Sciences.
"I am very pleased to announce the well-earned promotion of Dr. Michael Sabolinski to the role of Chief Medical Officer," commented Dr. Loberg. "Michael has demonstrated excellence in many areas, including his instrumental role in guiding BiDil® through the FDA regulatory approval process. His skills and expertise were particularly apparent during the Cardio-Renal Advisory Panel preceding BiDil's approval in June of last year. I am pleased that the Company will continue to benefit from the expertise of both Drs. Sabolinski and Worcel."
About NitroMed, Inc.
NitroMed of Lexington, Massachusetts is a research-based emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil® is indicated as an adjunct to current standard therapies such as ACE inhibitors and/or beta blockers. BiDil® was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company's landmark A-HeFT (African American Heart Failure Trial) clinical trial, and is marketed by NitroMed through a nationwide, dedicated sales force.
The Company is committed to the development of novel pharmaceuticals and safer, more effective versions of existing drugs to treat underserved patient populations. NitroMed's development efforts are primarily directed at expanding its cardiovascular franchise.
For full prescribing information, visit: www.BiDil.com. BiDil® is a registered trademark of NitroMed, Inc.
Forward Looking Statements
Statements in this press release about future expectations, plans and prospects for the Company, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the Company's ability to develop and maintain the necessary sales, marketing and manufacturing capabilities to launch and commercialize BiDil® or any of the Company's future product candidates; patient, physician and third-payer acceptance of BiDil® or any future product candidate as a safe and effective therapeutic; the Company's ability to obtain the substantial additional funding required to conduct development, manufacturing, marketing and sales of BiDil® or any future product candidates; unanticipated difficulties in maintaining regulatory approvals to market and sell BiDil® or obtaining such regulatory approvals for any of the Company's future product candidates; adverse side effects experienced by patients; the Company's ability to obtain or maintain intellectual property protection and required licenses and other factors discussed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2005, which has been filed with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.
Source: NitroMed
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
